H.C. Wainwright raised the firm’s price target on Minerva (NERV) to $7 from $4 and keeps a Neutral rating on the shares. The firm cites the “promising positioning” of the new schizophrenia study for potential approval and additional funding to support its progress for the target boost.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NERV:
- Minerva Neurosciences Warns of Major Dilution Risk From Preferred Stock Conversions and Warrant Exercises
- Minerva files $200M mixed securities shelf
- Vanguard Total Stock Market ETF (VTI) Daily Snapshot—3/11/26
- Minerva reports Q4 adjusted EPS (64c) vs. (53c) last year
- Vanguard Total Stock Market ETF (VTI) Daily Update—3/10/26